1 Min Read
Dec 19 (Reuters) - Biomarin Pharmaceutical Inc:
* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.